Global Glucagon-like Peptide 1 Market Report 2024: Market Size, CAGR, Lucrative Segments And Top Regions

Overview and Scope
Glucagon-like peptide 1 refers to a type of amino acid hormone of peptide that is produced in the L-cells of the intestinal epithelial endocrine. Glucagon-like peptide 1 is used to treat diseases and conditions such as diabetes and obesity respectively.

Sizing and Forecast
The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $19.51 billion in 2023 to $21.01 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%.  The  growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research..

The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $28.17 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%.  The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare.. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

Segmentation & Regional Insights
The glucagon-like peptide 1 market covered in this report is segmented –
1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users

North America was the largest region in the glucagon-like peptide 1 market in 2023. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp

Major Driver Impacting Market Growth
The rising prevalence of diabetes is expected to propel the global glucagon-like peptide 1 market going forward. Diabetes is a condition in which the blood sugar, or blood glucose, is too high. Glucagon-like peptide 1 is a medication used to treat conditions such as type 2 diabetes that may lead to weight loss and improved blood sugar. For instance, in January 2022, according to the National Library of Medicine, a US-based center of biomedical informatics and computational biology, it was estimated that global diabetes prevalence in 20-79-year-olds in 2021 was 10.5% (536.6 million people), and it is expected to increase to 12.2% (783.2 million) in 2045. Therefore, the rising prevalence of diabetes will drive glucagon-like peptide 1.

Key Industry Players
Major companies operating in the glucagon-like peptide 1 market report are Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

The glucagon-like peptide 1  market report table of contents includes:
1. Executive Summary

2. Glucagon-like Peptide 1 Market Characteristics

3. Glucagon-like Peptide 1 Market Trends And Strategies

4. Glucagon-like Peptide 1 Market - Macro Economic Scenario

5. Global Glucagon-like Peptide 1 Market Size and Growth

.

31. Global Glucagon-like Peptide 1 Market Competitive Benchmarking

32. Global Glucagon-like Peptide 1 Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market

34. Glucagon-like Peptide 1 Market Future Outlook and Potential Analysis

35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model